Ann Varanakis
Known title: Chief People OfficerCIK: 0001965703
Associated companies
Transaction History
| LFST | ▼ Sell | Tax Withholding | 8,156 | $99K | 8/24/2026 | View on chart |
| LFST | ▼ Sell | Tax Withholding | 8,707 | $60K | 3/9/2026 | View on chart |
| LFST | ▲ Buy | Grant | 26,836 | $0 | 3/9/2026 | View on chart |
| LFST | ▼ Sell | Tax Withholding | 11,232 | $78K | 3/9/2026 | View on chart |
| LFST | ▲ Buy | Grant | 59,789 | $0 | 3/9/2026 | View on chart |
| LFST | ▼ Sell | Tax Withholding | 25,024 | $173K | 3/9/2026 | View on chart |
| LFST | ▼ Sell | Tax Withholding | 21,566 | $149K | 3/6/2026 | View on chart |
| LFST | ▲ Buy | Grant | 86,331 | $0 | 3/5/2026 | View on chart |
| LFST | ▼ Sell | Open Market | 50,000 | $345K | 12/17/2025 | View on chart |
| LFST | ▼ Sell | Tax Withholding | 5,233 | $28K | 8/26/2025 | View on chart |
| LFST | ▼ Sell | Tax Withholding | 5,587 | $40K | 3/10/2025 | View on chart |
| LFST | ▼ Sell | Tax Withholding | 8,606 | $65K | 3/7/2025 | View on chart |
| LFST | ▲ Buy | Grant | 27,740 | $0 | 3/7/2025 | View on chart |
| LFST | ▲ Buy | Grant | 32,052 | $0 | 3/7/2025 | View on chart |
| LFST | ▼ Sell | Tax Withholding | 3,725 | $28K | 3/7/2025 | View on chart |
| LFST | ▼ Sell | Tax Withholding | 6,455 | $51K | 3/6/2025 | View on chart |
| LFST | ▲ Buy | Grant | 76,142 | $0 | 3/6/2025 | View on chart |
| LFST | ▼ Sell | Open Market | 5,269 | $33K | 8/23/2024 | View on chart |
| LFST | ▼ Sell | Open Market | 15,434 | $107K | 3/11/2024 | View on chart |
| LFST | ▲ Buy | Grant | 32,052 | $0 | 3/8/2024 | View on chart |
| LFST | ▲ Buy | Grant | 83,217 | $0 | 3/8/2024 | View on chart |
| LFST | ▼ Sell | Open Market | 5,661 | $43K | 8/24/2023 | View on chart |
| LFST | ▲ Buy | Grant | 96,153 | $0 | 3/6/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Keybanc Raises LifeStance Health Price Target to $15
Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.
Keybanc Raises LifeStance Health Price Target to $15. Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.